NCT04895046View on ClinicalTrials.gov

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 11, 2021

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2023

Conditions
HRDCholangiocarcinomaMetastatic Cancer
Interventions
DRUG

Niraparib

300 mg taken orally (all cycles)

DRUG

Dostarlimab

500 mg (cycles 1-4) intravenously

DRUG

Dostarlimab

1000 mg (cycle 5+) intravenously

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Emory University

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

lead

Walid Shaib, MD

OTHER

NCT04895046 - Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma | Biotech Hunter | Biotech Hunter